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Alzheimer’s disease is the most prevalent form of dementia. Neuropathogenesis is proposed to be a result of the accumulation of amyloid beta
peptides in the brain together with oxidative stress mechanisms and neuroinflammation. The presenilin proteins are central to the gamma-secretase
cleavage of the amyloid prescursor protein (APP), releasing the amyloid beta peptide. Point mutations in the presenilin genes lead to cases of
familial Alzheimer’s disease by increasing APP cleavage resulting in excess amyloid beta formation. This review discusses the molecular
mechanism of Alzheimer’s disease with a focus on the presenilin genes. Alternative splicing of transcripts from these genes and how these may
function in several disease states is discussed. There is an emphasis on the importance of animal models in elucidating the molecular mechanisms
behind the development of Alzheimer’s disease and how the zebrafish, Danio rerio, can be used as a model organism for analysis of presenilin
function and Alzheimer’s disease pathogenesis.
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Alzheimer’s disease (AD) is the most prevalent form of
dementia affecting more than 20 million people worldwide
[1,2]. Furthermore, as a consequence of the worlds aging
population, the prevalence of AD is expected to increase [1].
This highlights the importance of research investigating the
mechanisms behind the development of the disease. Apart from
the recognisable behavioural differences, it is difficult to
positively diagnose someone with Alzheimer’s during the
early stages of the disease [1]. However the AD brain shows a
consistent pathology amongst patients, with amyloid aggregates
and neurofibrillary tangles evident in the AD brain. Intense
research has identified genes involved in the development of
these pathologies, namely the amyloid precursor protein and the
presenilins. The increasing knowledge on AD pathogenesis has
revealed the complex nature of this disease and highlights the⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.12.001need to elucidate the molecular mechanisms involved. This
review discusses the current knowledge of the molecular
mechanisms of Alzheimer Disease, focusing on amyloidogen-
esis, the role of the presenilin genes and the importance of
animal models to further elucidate the mechanisms behind the
development of the disease.
The most common form of AD in the population
(approximately 90%) occurs sporadically and is late in onset,
usually occurring after 65 years of age [1,2]. Familial
Alzheimer’s disease (FAD), only accounts for approximately
10% of cases and symptoms usually occur before the age of 65
[1]. The mode of inheritance of AD differs for each type. The
majority of FAD and sporadic AD cases have a complex
inheritance, while only 10% of FAD cases are inherited in an
autosomal dominant pattern [3]. In affected individuals the
disease causes a progressive and permanent decline in memory
and cognitive abilities. The first cognitive area affected is
episodic memory [4]. During disease progression, attention,
executive functions, semantic memory, language and spatial
orientation all begin to deteriorate [5]. However the molecular,
cellular and pathological triggers for the onset of the cognitive
deterioration are poorly understood.
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Alzheimer’s disease was originally recognised by Alois
Alzheimer in 1907 as a separate form of dementia. Since this
original observation the two main histological features of
amyloid plaques and neurofibrillary tangles (NFT) have been
described in the AD brain [6]. These features are found to be
present in the temporal neocortex and hippocampal regions of
the AD brain [7]. The hippocampus resides in the cerebral
cortex of the forebrain and is thought to be involved in memory
storage. Amyloid plaques and NFTs result from an aberration in
deposition of the amyloid beta peptide (Aβ peptide) and the
hyperphosphorylated tau protein respectively and these deposi-
tions lead to neuronal loss and neurotoxicity in the AD affected
brain [8]. Accumulation of Aβ peptides may be the key event in
pathogenesis of AD. The exact mechanism by which Aβ
peptide deposition induces neurotoxicity is unclear, but it
appears the oxidative stress plays an important role. Oxidative
stress is extensive in AD [9,10] and Aβ peptides stimulate
oxidative stress by both direct and indirect mechanisms. Aβ
peptides by themselves may act as enzymes [11], as they are
capable of directly producing hydrogen peroxide and generating
free radicals through metal ion reduction [12,13]. As well, Aβ
peptide can bind to mitochondrial proteins resulting in the
generation of free radicals [14]. Furthermore, Aβ peptides
generate oxidative stress via neuroinflammation. Considerable
evidence has supported that neuroinflammation is associated
with AD pathology [15]. The death of neurons observed in AD
is partly attributed to the activation of two major brain cell
types, astrocytes and microglia that participate in the immune/
inflammatory response to Aβ deposition. However, these cells
can have both neuroprotective and neurodegenerative functions.
For example, astrocytes cluster at sites of amyloid deposition
and are thought to be involved in the clearance of plaques,
evident through their ability to degrade amyloid beta deposits in
vitro and in situ [16]. Both astrocytes and microglia release pro-
inflammatory molecules upon activation, in particular, astro-
cytes can be activated by amyloid beta deposits to produce
reactive oxygen species, as well as chemokines, cytokines, that
lead to neuronal cell death [17]. Aβ peptides also induce the
expression of nitric oxide synthase in microglia and the release
of reactive nitric oxide which results in the loss of selected
neuron populations [18]. Furthermore, Aβ peptides stimulate
microglial cells to release a neurotoxin, quinolinic acid [19],
which may also play a role in neurotoxicity.
2.1. The amyloid cascade hypothesis
The amyloid beta hypothesis predicts that an aberration in
the proteolytic processing of the amyloid precursor protein
(APP) leads to the increased production of Aβ peptides, this in
turn leads to the accumulation of Aβ, a primary event in the
pathogenesis of AD [1]. The accumulated Aβ eventually
deposits into amyloid plaques present in the AD brain
parenchyma. Together with the secondary events of microglial
and astrocyte activation and NFT formation there is widespread
neuronal dysfunction and selective neuronal loss. Currently, thishypothesis is being referred to as the Aβ cascade hypothesis,
where increased production and possibly decreased clearance of
Aβ peptides leads to an accumulation of these peptides and the
subsequent pathogenesis observed in AD.
APP is a ubiquitously expressed type I integral membrane
glycoprotein with various major isoforms. The largest of the
APP alternate transcripts comprises an alternatively spliced
exon at residue 289 which contains a serine protease inhibitor of
the Kunitz type (KPI) [20]. APP resides on chromosome 21 and
Down’s syndrome cases (caused by an extra copy of 21) have
been shown to develop early onset dementia. This observation,
in conjunction with other studies lead to the discovery of the
first reported partial amino acid sequence of Aβ in 1984 [21].
APP is expressed abundantly in a variety of tissues and
processing of APP is a normal event in nearly all neural and
non-neural cells throughout the body. Proteolytic processing of
APP that releases the Aβ fragment is a result of cleavage events
by secretase proteins. APP processing by the secretase proteins
occurs in two distinct pathways, the non-amyloidogenic and
amyloidogenic pathways. Soluble APP is cleaved by α-
secretase and β-secretase to release the soluble α-APP and
β-APP, respectively, into the extracellular matrix [22]. In the
non-amyloidogenic pathway, γ-secretase cleavage of the
remaining C-terminal fragment (CTF) releases the p3 fragment,
while in the amyloidogenic pathway this cleavage releases the
Aβ peptide (Fig. 2). The cleavage by γ-secretase is a
heterogenous event that releases Aβ peptides of different
sizes, with Aβ-40 and Aβ-42 being the most common forms.
Aβ-40 and Aβ-42 are both toxic peptides, however the Aβ-42
isoform is insoluble and more capable of aggregating into
amyloid plaques. Upon accumulation of Aβ-42 there is a
resulting neuronal cytotoxicity that induces neuropathological
events leading to neurodegeneration of the brain [23]. More
specifically, Aβ-42 can aggregate into two different conforma-
tion states. There is the non-β sheet, non-fibrillar state and the β
sheet fibrillar state which is cytotoxic and eventually deposits
into plaques [24]. Aβ-42 exists initially as a monomer, during
oligomerisation the monomers further oligomerise into larger
forms such as large oligomers, protofibrils and fibrils. During
oligomerisation there are conformational changes occurring in
these elements that transform them into a β sheet fibrillar state
[23]. The Aβ oligomeric intermediates (oligomers, protofibrils)
and the mature fibrils are all neurotoxic, and it has been
demonstrated that the oligomers and protofibrils are actually
more neurotoxic than the mature fibrils or amyloid plaques [25].
2.2. Genes implicated in Alzheimer’s disease
Three genes that have been implicated in AD pathogenesis
are APP, presenilin 1 (PS1) or presenilin 2 (PS2), as mutations
in these genes have been identified in cases of familial AD [26].
PS1 is central to the γ-secretase complex of proteins that cleave
Notch and APP [27]. It is the presenilin-mediated cleavage of
APP that results in the release of various lengths of the Aβ
peptide. The pathological characteristics of FAD and the
sporadic form of AD are proposed to be similar; therefore
somatic changes in APP, PS1 or PS2 may potentially have a role
ig. 1. Amyloid ß-protein (Aß) can accumulate through over production (e.g.,
resenillin mutation [PSENmut]) or reduced removal (e.g., APOE4). Oligomer-
ation of Aß results in production of oxidative stress by itself (which can be
ugmented by heavy metals), of via induction of several other interacting
echanisms.
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PS1, PS2 and APP, the apolipoprotein (APOE) gene has been
identified as a major genetic risk factor for sporadic AD. E4 is
an isoform of APOE and carriers of the E4 allele are at a higher
risk of developing AD, with homozygotes usually developing
AD earlier than heterozygotes [28]. However the presence of
the APOE4 allele, has not been found to be necessary or
sufficient for the development of the disease [28].
The gene encoding APP was the first to be identified has
having an association with FAD. Currently there are 27
mutations in the APP gene that have been described in families
with AD and these mutations are clustered around the Aβ
sequence on APP [29]. Mutations in PS1, PS2 and APP account
for approximately 50% of Familial AD cases and there is
almost 100% penetrance of the mutated gene product that leads
to AD development [29]. Worldwide studies on FAD cases
have uncovered 157 and 10 pathogenic mutations in the PS1
and PS2 genes respectively (http://www.molgen.ua.ac.be/
ADMutations/)[30]. The presenilin section of this review
discusses presenilin associated FAD mutations in more depth.
In vitro and in vivo models of familial AD mutations have
demonstrated an enhancement of APP proteolytic processing
through aberrations of the γ-secretase complex [31,32]. These
alterations generally increase the production of Aβ-42 or
decrease the production of Aβ-40, which results in changes to
the Aβ-40/Aβ-42 ratio, an important aspect of AD [33,34]. A
shift in APP processing to release the longer Aβ-42 isoform
leads to Aβ fibril formation [32,35]. These mutations usually
have a familial inheritance pattern. For example, a mutation in
APP identified in a Swedish family alters two amino acids that
precede the Aβ amino terminus and results in enhanced β-
secretase cleavage, causing an increase in Aβ production [36].
Aβ peptides with the Flemish mutation assemble into fibrils and
protofibrils at a slower rate compared to wild type [37], while in
the Dutch mutant, Aβ protofibrils and fibrils are formed at a
much faster rate than wild type [38]. Theuns et al. [33] have to
date reported the furthermost C-terminal APP K724N mutation.
In vitro expression analysis of this mutation displayed an
increase in Aβ-42 and decrease in Aβ-40 levels, which
increased the Aβ-40/Aβ-42 ratio three-fold [33]. Even though
these mutations are located on adjacent codons on APP, they
produce different pathological characteristics in the patient
population.
2.3. Linking oxidative stress with Alzheimer’s disease
Oxidative stress is associated with a wide range of disease
states including cancer, diabetes and neurodegenerative dis-
orders such as AD. Oxidative stress results from a disturbance in
the balance of antioxidants and reactive oxygen species (ROS)
generated within the body, resulting in an excess of ROS. This
leads to the destruction of both neuronal and vascular cells [11].
Oxidative stress disturbs the normal functioning of cells through
cell membrane lipid destruction and cleavage of DNA [39].
Whether oxidative stress is involved at the onset of AD is still
unclear. However it is thought to play a significant role during
disease progression, particularly in cellular and tissue damagethat occurs throughout AD. As noted above, oxidative stress is
extensive in AD. It has also been suggested that there is a close
correlation between oxidative stress and Aβ deposition, evident
through mouse brain Aβ deposits co-localising with a variety of
oxidative stress markers [40]. Aβ is proposed to be a
metalloenzyme that is capable of generating hydrogen peroxide
through its superoxide dismutase activity [11]. Hydrogen
peroxide is capable of being further transformed to the reactive
hydroxyl radical in the presence of transition metals, following
this transformation lipid peroxidation reactions bring about
oxidative damage, leading to oxidative toxicity in neurons [11].
It has been further suggested that oxidative stress may actually
promote the amyloidogenic pathway [11], the resulting increase
in Aβ can in turn generate more hydrogen peroxide leading to
further oxidative damage in neurons and vascular cells. A cyclic
pathway of excess Aβ promoting oxidative damage which
promotes further Aβ production would result in heightened
neurotoxicity and subsequently enhance the development of AD
[11]. As discussed above, Aβ can produce oxidative damage by
stimulating neuroinflammation, as well as generating ROS as a
result of binding to mitochondrial proteins. Furthermore,
intermediate amyloid aggregates can interact with cell mem-
branes, where they form non-specific ion channels, with the
resultant increases in intracellular calcium triggering the
production of ROS [41]. Thus there is a strong link between
Aβ, oxidative stress and AD (see Fig. 1).
2.4. Alternative initiating mechanisms for the amyloid cascade
hypothesis
Apart from the identified FAD point mutations there is
evidence that other neurochemical factors may initiate the
deposition of Aβ in FAD or sporadic AD. The following areF
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contribute to or initiate the development of neuropathological
features of AD.
2.4.1. The role of vascular dysfunction and risk factors for AD
pathogenesis
Cardiovascular disease and type 2 diabetes are risk factors
for AD. Vascular risk factors such as hypertension and
hypercholesterolemia are proposed to promote the production
of Aβ [42,43], while being overweight or obese is also now
associated with AD [44,45]. Vascular risk factors appear to be
exacerbated by the inheritance of the E4 allele of the APOE
gene, thus the presence of this allele increases the risk of
developing both vascular dysfunction and AD [43]. A recent
study by Balakrishnan et al. [46] investigated whether being
overweight or obese contributes to AD development by
modulating Aβ levels. In their study of 18 adults they found
a correlation between the direct measures of obesity and plasma
levels of Aβ-42 [46]. This is the first study to suggest that being
overweight and obese is a risk factor for developing AD by
increasing plasma levels of Aβ-42.
Recent findings have also suggested that neurovascular
dysfunction is an important feature of chronic neurodegenera-
tion in AD [47]. The neurovascular hypothesis as suggested by
Zlokovic et al. [47] proposes that there is faulty clearance of Aβ
across the blood brain barrier (BBB). In one instance the faulty
clearance, possibly due to aberrant angiogenesis, results in
increased Aβ levels. Furthermore, another pathway could
involve increased Aβ concentration in conjunction with
atherosclerosis. Together, these mechanisms are proposed to
cause premature aging of the cerebrovascular system [47]. Both
of these cascades could initiate neurovascular uncoupling,
vessel regression, brain hypoperfusion and neurovascular
inflammation [47]. Flow on effects include compromise of the
BBB, an ionic imbalance and metabolic poisoning in the brain
interstitial fluid, finally leading to synaptic dysfunction and
neuronal injury and loss, evident pathologies in AD [47].
2.4.2. Redox active metals are key mediating factors in the
pathophysiology of AD
It is likely that there is a pathological interaction of Aβ with
redox active metals such as zinc, copper and iron, due to these
metals having a high concentration in the areas of the brain that
are affected by AD, namely the cortex, hippocampus and
cortical vasculature [48,49,50]. Redox active metals may play a
role in oxidative stress as they influence the production of
hydrogen peroxide [24] (see Fig. 1). The binding of trace levels
of these metals to Aβ, promotes the catalytic production of
hydrogen peroxide from oxygen through metal reduction [13].
The effect of these metals on the oxidative mechanisms of Aβ
cytotoxicity is complex and not yet fully elucidated, however
the effect of zinc on AD pathology may be explained by ‘The
Zinc Paradox’ [24]. During normal physiology, zinc, copper and
to a lesser extent iron interact with APP and Aβ, probably
existing in a delicate balance. Perturbations in this balance may
result from abnormal Aβ metabolism and synaptic zinc
flooding, resulting in a change in zinc and copper metabolismleading to the formation of fibrillar Aβ. Consequently, this fibril
formation triggers an inflammatory response that lowers pH and
leads to a disruption of zinc homeostasis [24]. Zinc is released
into the cellular environment and this triggers events that lead to
oxidative stress-induced cell death [51]. Copper ions are then
free to compete for zinc’s binding site on Aβ and these ions can
then catalyse hydrogen peroxide production by Aβ. Zinc is
essential in human nutrition; however the role of cerebral zinc in
AD pathology requires further elucidation. Since it has been
established that zinc is elevated in cored amyloid plaques [52]
and zinc flooding can lead to increased Aβ fibril formation and
oxidative stress, zinc may, paradoxically, be a pathological
factor for AD.
3. The presenilin proteins
In humans the PS1 gene resides on chromosome 14 [53] and
the PS2 gene resides on chromosome 1 [54,55]. Presenilin
proteins are evolutionarily conserved amongst species. Pre-
senilins are transcribed in both the central nervous system and in
non-neuronal organs. Presenilin functions within the γ-
secretase complex, with the mature complex predominantly
existing at the cell surface regulating the cleavage of a number
of single transmembrane domain proteins [56]. Furthermore
presenilin (as a part of the γ-secretase complex) is also found to
reside in the membranes of the endoplasmic reticulum and
Golgi apparatus [57]. In vitro generated point mutations in the
PS1 gene leads to an increased production of Aβ peptides
[58,59,60] and there is a reduction in γ-secretase cleavage of
APP in neuronal cultures derived from PS1 deficient mice
embryos [61]. These findings and more led to the conclusion
that mutations in PS1 have a gain-of-function phenotype and
that PS1 is a target for anti-amyloidogenic therapy in AD. It
now is well substantiated that presenilins functions in the γ-
secretase cleavage of APP, however, the complete function of
PS1 and PS2 has not yet been determined. PS1 and PS2 are
highly homologous and share 62% amino acid identity. Upon
deletion of PS1 and PS2 in the forebrain of mice, there is a
severe phenotype that resembles a Notch gene knockout [62].
There are also evident biochemical alterations of neuronal
atrophy, astrogliosis, caspase-3-mediated apoptosis and tau
hyperphosphorylation [63]. Together these alterations demon-
strate that the presenilins are essential for the ongoing
maintenance of cortical structures and function in the brain
[63]. Presenilins are also involved in several cell-signalling
pathways with an essential function during development [64]
and they regulate β-catenin stability and trafficking of
membrane proteins [65,66]. Presenilin has also been implicated
in calcium signalling. Tu et al. [67] recently demonstrated the
presenilin holoprotein accounting for ∼80% of in Ca2+ leakage
from the ER. Interestingly it appears to be independent of its γ-
secretase activity [67].
Presenilins have also been implicated in different apoptotic
pathways. A partial cDNA clone encoding a portion of PS2
CTF rescued a T-cell receptor and FAS-induced apoptosis [68].
Furthermore, PS is implicated in mitochondria-dependent
apoptotic cell death, through its interactions with the anti-
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presenilins’ involvement in apoptotic processes has been
demonstrated, the actual mechanism of their apoptotic function
is yet to be elucidated (Fig. 2).
The SEL-12 protein, a presenilin homologue, is expressed
throughout the nematode Caenorhabditis elegans (C. elegans).
Due to the almost identical function of SEL-12 and human PS1,
the study of SEL-12: LacZ fusion proteins has predicted the
topology of the PS1 protein to encompass eight transmembrane
(TM) domains, with a hydrophilic loop between the sixth and
seventh domain [71]. Other topological studies using a similar
experimental design that probes for membrane topology by
using the glycosylation of PS1 hybrid proteins, have suggested
models of the presenilin protein ranging between 6 and 9 TM
domains [72–75]. The conserved aspartate residues Asp 257 in
TM6 and Asp385 in TM7, appear to contain the active site of
PS1 that contributes to γ-secretase activity and the region
between these two residues is critical for PS1 endoproteolysis. It
has been demonstrated that mutations in either of the two
aspartate residues prevent endoproteolysis of PS1 in the
cytoplasmic loop, substantially reduce the production of Aβ
and decrease Aβ secretion by 60% [76], while mutating an
equivalent aspartate in PS2 results in undetectable levels of Aβ
[77]. The major endoproteolysis site of the PS1 holoprotein has
been identified as residue 298 located in the large hydrophilic
loop [78].
Presenilin is translated as a full-length holoprotein which is
predominantly endoproteolytically cleaved by presinilinase into
the 27-kDa N-terminal (NTF) and 17-kDa CTF [79]. The site of
endoproteolysis has been shown to be in the exon 9 hydrophilic
loop region, since a PS1 variant lacking exon 9 did not undergo
endoproteolysis [79]. Endoproteolysis appears to be the critical
event that brings about PS1 stability and biological activity as
antibody staining of specific sections of presenilin has indicated
that there is very little full-length PS1 or PS2 protein detected in
brain tissue [78]. Ratovitski et al. [80] demonstrated that
presenilin NTF and CTF are significantly more stable then the
full-length polypeptide in mouse cell lines expressing human
presenilin. Thus, presenilin is mainly present as N- and C-Fig. 2. Processing of APP in the amyloidogenic pathway. Cleavage of APP by
secretase enzymes releases the amyloid beta peptide, excess peptides eventually
deposit into amyloid plaques.terminal endoproteolytic fragments. These fragments dimerise
to form the active, functional presenilin heterodimer [78]. As a
consequence of the heterodimer formation the fragments are
protected from the relatively rapid degradation that is evident
for the holoprotein [81]. PS1 is able to form both low (100–
180 kDa) and high (>250 kDa) molecular weight complexes
that can contain the full length or the heterodimeric CTF and
NTF fragments [81,82]. Furthermore the formation of the
higher molecular weight complex appears to be required for
presenilin mediated cleavage of APP and the signal receptor
Notch (described in detail later). Hebert et al. [83] have
proposed a hypothetical model of PS1 maturation that is in
accordance with a model proposed by Haas and Steiner et al.
[84]. In this model, PS1 homodimerises before the full-length
protein is endoproteolytically cleaved by presinilinase. A
tetramer of hetero and homodimers would then be required
for the assembly and stability of the high molecular weight
complex needed for γ-secretase activity [83]. Through yeast
two hybrid and split-ubiquitin assays, Cervantes et al. [85] have
also observed NTF: NTF and CTF: CTF dimers. Subsequently,
a tetramer model of the presenilin functional complex was
proposed and further analysis of the effect of FAD mutations on
NTF: NTF homodimerisation displayed these mutations affect-
ing the NTF: NTF interaction. This result implies that FAD
mutations influence the assembly or possibly the stability of the
functional presenilin complex.
3.1. Presenilin is integral to the γ-secretase complex
γ-Secretase is a transmembrane aspartyl protease that exists
as a mature complex within the plasma membrane, where it
interacts with and cleaves single transmembrane receptors such
as Notch and APP [56]. Prior to cleavage these substrates
undergo a shedding of a large ectodomain leaving a membrane-
embedded CTF. The CTF is subject to intramembrane cleavage
by the γ-secretase complex, the proteolytic cleavage releases an
intracellular domain that is able to modulate transcription [86].
Findings by Kimberly et al. [87] suggest that four
membrane proteins comprise the γ-secretase complex and
these enzymes co-assemble to form the active complex in
mammalian cells. Currently it is thought that the higher
molecular weight complex that PS1 forms contains the
proteins nicastrin (NCT), anterior pharynx defective (APH-1)
and presenilin enhancer 2 (PEN2). Through multistep affinity
purification of γ-secretase, the PS, NCT, APH-1 and PEN-2
proteins were shown to co-purify as a complex [88].
Overexpression studies of APH1a, APH1b, PEN2 and NCT
DNA in HEK293 cells, resulted in an increase in the
production of Aβ-40 and Aβ-42, suggesting that these
proteins are limiting for γ-secretase activity. Overexpression
of APH-1 in S2 cells of the fruit fly Drosophila melanogaster
results in a marked increase in the PS1 holoprotein that is
further enhanced by overexpression of NCT [89]. RNAi
depletion of PEN2 in S2 cells, mammalian neuronal cells and
mouse neuroblastoma cells results in an accumulation of the
full length PS protein, thus preventing endoproteolysis [89].
Furthermore, RNAi-mediated inactivation combinations in S2
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this accumulation [89]. Interestingly, when NCT is deleted in
C. elegans or Drosophila, the resulting phenotypes are similar
to the loss of PS1 or Notch [90,91]. Cleavage of APP and
Notch at the γ-secretase cleavage site is also eliminated,
together with a loss of PS1 endoproteolysis and maturation
[90]. This is also evident in NCT null mouse embryos. These
embryos have severe developmental defects and die by
embryonic day 10.5 [92]. Furthermore, embryonic fibroblast
cells isolated from these NCT null mice have decreased levels
of APH-1, PEN-2 and PS1 fragments together with a
significant accumulation of full-length PS1 [93]. Collectively,
these results implicate APH-1 as acting in the stabilisation of
the PS holoprotein in the complex, while PEN-2 and NCT
assist the endoproteolysis of PS1, thus providing γ-secretase
activity. Recently, Chen et al. [94] discovered a new member
of the γ-secretase complex, a type 1 transmembrane protein
named TMP21 that is a member of the p24 cargo-family. It
was isolated in a high molecular weight presenilin complex
and was shown to interact with all of the complex
components. They demonstrated that overexpression of
TMP21 had no effect on the levels of the other complex
components or Aβ production, however suppression by small
interfering RNAs increased the production of Aβ40 and
Aβ42. Thus, through its interaction within the γ-secretase
complex TMP21 appears to modulate Aβ production [94].
PS1 has homology to part of an active site of a known
bacterial aspartyl protease [95].
Notch proteins are a group of large cell-surface receptors that
are required for cell-fate decisions during development.
Following binding to its ligand on the cell surface, Notch-1
undergoes γ-secretase cleavage at site 3 (S3) within its
intracellular domain to release the Notch intracellular domain
(NICD) fragment [96]. NICD then translocates to the nucleus
and interacts with DNA-binding proteins to regulate transcrip-
tion. Mutations in the SEL-12 protein of C. elegans result in an
egg laying defect, indicating a loss of Notch function.
Expression of human PS1 or PS2 in these mutants rescues the
egg laying defect. However, in the presence of FAD point
mutations there is an observed reduction in rescue [65].
Knocking out PS in Drosophila results in phenotypes identical
to Notch null mutants [97]. Therefore, PS is required for Notch
function and presenilin’s function in notch signalling is
conserved between humans, C. elegans [98] and Drosophila.
A diverse range of additional cell surface proteins have been
identified as γ-secretase and presenilin substrates. There is little
in common between these substrates except that they all posses
single transmembrane domains. Deleted in colon cancer (DCC),
ErbB4, Delta and p75 neurotrophin receptor (p75NTR) are γ-
secretase substrates known to influence neuronal structure and
function and are important for development of the nervous
system. However the role of cleavage of these proteins by γ-
secretase is unknown [99]. Even though it can be postulated that
perturbations in the γ-secretase mediated cleavage of these
proteins may affect neuronal function, currently an association
of these molecules with neurodegeneration or AD development
has not be established.3.2. Presenilin mutations and alternative splicing in
Alzheimer’s disease
The majority of missense mutations identified in FAD occur
at highly conserved sites [100] and are spread throughout the
gene. The mutations identified in PS1 are spread through TM
domains 1–6 and also in the N and C-terminus, while in PS2 the
FAD mutations are present in TM domains 2 and 5 and a
mutation identified in a sporadic case of AD is found at the N-
terminus [29]. Interestingly, approximately 21% of PS1 AD
associated mutations and 4 out of 10 reported PS2 mutations are
found in exon 5 [64]. Therefore this region may hold some
importance in regard to structure and function of presenilin
within the lipid bilayer as exon 5 resides in transmembrane
domain 2 of PS1 and PS2 [64]. Presenilin mutations also disturb
protein interactions in the γ-secretase complex through
conformation changes that affect APP processing [29] and
alter the Aβ40/42 ratio either through in an increase in Aβ-42 or
a decrease in Aβ-40 [33,34,60]. This is evident through a
consistent overproduction of Aβ-42 peptides in brain tissue of
FAD patients [29] and transgenic mice harbouring a human PS1
mutation [3]. Furthermore, cultured cells transfected with
mutant PS1 or PS2 have a 1.5 to 5 fold increase in the
intracellular concentration of Aβ 1–42 compared to cells with
wild type PS1 or PS2 [29].
The alternative splicing of exons within a gene, results in the
production of different protein isoforms. The isoforms may
share or differ in function from the original protein [101]. Splice
variants have been identified in PS1 and PS2. In human brain
tissue of sporadic AD patients a splicing variant of PS2 (PS2V)
has been detected. This variant is preferentially expressed and
lacks exon 5 [101]. Due to the exclusion of exon 5 a frameshift
occurs in exon 6, resulting in a PS2V containing residues Met1
to Leu119 which is encoded by the amino terminal and a further
five additional residues at its carboxyl terminus [102]. In the
study by Sato et al. [101] 83% of the variant positive cases had
sporadic AD and in neuroblastoma cells the spliced variant was
detected under hypoxic conditions. Upon antioxidant treatment,
there was an inhibition of the hypoxia induced spliced variant
[101]. Interestingly a study by Matsuzaki et al. [103] showed
that the PS2V induced by hypoxia can be accelerated by chronic
exposure to aluminium. The resulting cell death from this
exposure is due to the hypoxic conditions and can be partly
attributed to oxidative stress. Considering that aluminium is not
a necessary metal for cell function, this result may indicate that
chronic aluminium exposure is an environmental risk factor for
the development of AD [103].
Kwok et al. [104] discovered an early-onset FAD case that
had a novel missense mutation (L271V) present in PS1. Exon
trapping analysis confirmed that this mutation results in altered
exon 8 splicing and a variant neuropathology in the pedigree.
Neuropathological analysis demonstrated the presence of large
non-cored plaques, which indicate diffuse plaques rather then
the typical neuritic amyloid plaques. Western blots of cell
lysates immunoprecipitated with anti-tau or antiGSK-3β
indicated that wildtype but not exon 8-deleted PS1 is able to
interact directly with Tau and GSK-3β. This supports the idea
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GSK-3β phosphorylates tau and initiates neuritic dystrophy,
PS1 exon 8 appears to be necessary for neuritic plaque
formation. Biochemical analysis indicated that this mutation
increased the production of the Aβ-42 peptide [104]. A novel
variant of PS1 in an AD Finnish pedigree has also presented
with diffuse plaques. Through molecular analysis it was
demonstrated that this variant had a deletion of exon 9 [105].
Therefore, it appears that the loss of either exon 8 or 9 results in
AD with diffuse plaques lacking the dense neuritic core of Aβ,
implying that this region of presenilin has some role in neuritic
plaque development. The presence of diffuse rather then
neuritic plaques in these cases provides further evidence that
the pathogenic events of AD occur before the aggregation of Aβ
into neuritic plaques.
3.3. Aberrant presenilins are implicated in other disease states
Aberrant splicing events in the PS1 gene have been observed
in other neurological disorders. The presence of PS1 gene
products that have deletions in the exons 4–8 region have been
found in the brain of sporadic cases of frontotemporal dementia
(FTD) [106]. As previously mentioned this disorder has NFTs
present in the brain with no detection of amyloid plaques.
Furthermore, the increased expression of the PS2V isoform
detected in the brains of sporadic AD patients, has also been
detected in the cortex at significantly elevated levels in some
bipolar and schizophrenia cases [64] A novel mutation in PS1
(Gly183Val) was identified in a patient with a Pick type
tauopathy, with the absence of Aβ plaques [107]. This mutation
affects the splice signal of the sixth exon intron junction, which
may result in aberrant splicing. Preliminary analysis of
alternatively spliced products revealed a premature stop codon
downstream of exon 5 [107]. These aberrantly spliced
presenilins are toxic to normal presenilin function possibly
through a loss of function or dominant negative affect. These
findings implicate aberrant splicing of the presenilins in
neurodegeneration together with its already documented role
in development.
A casual link between neurodegenerative and cerebrovas-
cular diseases has been consistently suggested when analysing
these types of disorders, with vascular risk factors being
identified has possible risk factors for AD pathogenesis [108].
Recently Rovelet-Lecrux et al. [109] demonstrated duplication
of the APP locus in five families. These individuals develop
early-onset AD with cerebral amyloid angiopathy (CAA). CAA
is a disease where Aβ peptides deposit in the walls of small
blood vessels in the brain leading to stroke, haemorrhages and
dementia. Individuals with an APP duplication either present
with dementia or intracerebral haemorrhages or a mixture of
both phenotypes [109], thus suggesting a link between dementia
(AD) and the vasculature of the brain. Missense mutations in the
Notch 3 gene have been attributed to the vascular disease,
cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) [110]. The
common symptoms of this disorder are migraines, ischemic
strokes, mood disorders and progressive cognitive impairmentthat results in dementia [111]. Along with dementia progression,
a further link to neurodegenerative disorders is evident though
recent research identifying the basis of CADASIL as being a
degenerative disorder of brain vessels [108]. Interestingly, the
intramembrane region of Notch 3 possibly undergoes presenilin
mediated γ-secretase cleavage, similar to the cleavage events of
APP in AD pathogenesis. The role of Notch in vascular integrity
and the role of presenilin in Notch signalling suggest the
existence of molecular commonalities between these two
diseases.
3.4. Presenilin regulation of the Wnt/β-catenin signalling
pathway
The armadillo homologue, β-catenin is an effector molecule
in the Wnt/Wingless signalling pathway. It is a transcription
factor bound at the cell membrane, where it is involved in the
maintenance of the link between the cadherins and the actin
cytoskeleton [112]. β-catenin is also located in the cytoplasm in
a complex with GSK3-β. Phosphorylation by GSK3-β
promotes the ubiquitination of β-catenin, which in turn leads
to the rapid degradation of β-catenin by the proteosome [113].
However GSK3-β can be inhibited by signalling through the
soluble ligand, Wnt. Inhibition by Wnt results in the
accumulation of unphosphorylated β-catenin in the cytoplasm,
which eventually translocates to the nucleus. In the nucleus β-
catenin binds to the LEF/TCF family of transcriptional
regulators that activates target genes of Wnt.
Together with its role in intramembrane proteolysis of Notch
and APP [27], PS1 also regulates protein degradation of β-
catenin in the Wnt signalling pathway [114,115]. Co-immuno-
precipitation experiments have demonstrated thatβ-catenin binds
to the loop domain of PS1 coded by exons 8, 9 and 10 [116]. The
functional relevance of this binding has been contradictory where
PS1 FAD mutations have either increased β-catenin degradation
[117] or interfered with the turnover of β-catenin leading to its
accumulation [118]. Using PS1 knockout fibroblasts, Soriano et
al. [115] convincingly demonstrated β-catenin accumulating in
the cytoplasm with activation of LEF/TCF gene transcription.
This indicates that PS1 negatively regulates Wnt/β-catenin
pathway [115]. This is further supported by the evident
accumulation of armadillo (Drosophila homologue of β-catenin)
in presenilin-deficient Drosophila embryos [114]. It has been
speculated that PS1 is needed for the phosphorylation of β-
catenin, however Soriano et al. [115] demonstrated an accumula-
tion of phosphorylated β-catenin in the PS1 deficient cells.
Furthermore in the presence of a proteosome inhibitor there are
lowered levels of ubiquitinated β-catenin observed in PS1
deficient cells compared to wild type cells, which suggested that
PS1 is possibly required for the ubiquitination ofβ-catenin [115].
How PS1 affects the Wnt/β-catenin pathway and furthermore
how Aβ production is affected by the interaction between PS1
andβ-catenin still remains to be elucidated, though it does appear
that this interaction functions in multiple signals that lead to cell
fate decisions [35]. The loss ofWnt signalling does appear to play
a role in AD [39], evident through the neurotoxicity of Aβ
aggregation in hippocampal cells being linked to an increase in
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3β mediates the phosphorylation of tau, the increase in GSK-3β
due to Aβ aggregation may contribute to the formation of NFTs.
Overexpression of dishevelled, a downstream transducer of Wnt
signalling, inhibits GSK-3β mediated phosphorylation of tau,
demonstrating a possible role in increasing neuronal protection
during neurodegenerative disorders together with its role in
regulating notch signalling [119].
4. Animal models of Alzheimer’s disease pathogenesis
Reliable animal models are required to facilitate the under-
standing of neurodegenerative pathways in AD. Models should
allow for the testing of compounds at various points of the
pathogenetic cascade in order to search for disease modifying
drugs. Furthermore, they remain an invaluable tool for
identifying molecular, cellular and pathological changes that
trigger the onset of cognitive decline in AD. Specifically, the
presenilin gene is highly conserved during evolution, with
orthologues in mouse, C. elegans and Drosophila [100]. Danio
rerio, more commonly known as zebrafish, has two orthologues,
zebrafish psen1 [120] and zebrafish psen2 [121]. Transcripts
from these genes have been demonstrated in zebrafish embryos,
suggesting their requirement for development [122].
Drosophila and C. elegans models have been explored to
investigate aspects of AD neuropathology. Recently Crowther
and colleagues [123] developed a Drosophila model, in which
human Artic mutant Aβ production is driven in the CNS and
retina. This expression results in intracellular Aβ accumula-
tion and non-amyloid aggregates that resemble diffuse
plaques. These histological changes are associated with
progressive locomotor deficits and premature death, indicating
that the accumulation and aggregation of Aβ is sufficient to
cause aspects of Aβ pathogenesis [123]. Moreover the fly
phenotype is rescued by congo red, a dye that had been
previously shown to reduce Aβ aggregation in vitro [123]. A
study by Finelli et al. [124] examined the overexpression of
Aβ-42 in Drosophila nervous system tissues. Overexpressing
Aβ-42 in the eye resulted in a rough eye phenotype that
worsened with age. There was also evidence of insoluble
aggregates forming in the photoreceptors. Flies overexpressing
Aβ-42 in the brain had a reduced life span in comparison to
control flies [124].
C. elegans possesses three orthologues of human presenilin,
sel-12 [98], hop-1 [125] and spe-4 [126,127]. Complete
presenilin function is evident in the SEL-12 protein as human
PS1 and PS2 substitute for SEL-12 activity in C. elegans. Also,
as previously mentioned, the structure of the SEL-12 protein
was used to determine the transmembrane domains of human
PS1. In 1995, Link et al. [128] generated a C. elegans model of
Aβ molecular pathology by genetically engineering animals to
express human Aβ specifically in muscle cells. These
nematodes produce muscle specific Aβ deposits that are
immunoreactive with monoclonal and polyclonal anti-Aβ
antibodies. The transgenic nematode larvae present with
progressive muscle paralysis and vacuoles, phenotypes that
can be attributed to toxicity in muscle cells [128].4.1. Mouse models of AD neuropathology
There have been numerous transgenic mice developed that
model phenotypes observed in AD. Oddo et al. [129] developed
a triple-transgenic model in which cDNA from human APP
Swedish mutation and human P301L Tau mutation were co-
microinjected into embryos from homozygous mice with a
human PS1 AD knock-in mutation [129]. This method
generated triple transgenic mice with the same genetic
background. Further studies showed that these mice present
with amyloid plaques and NFTs in AD-relevant regions of the
brain. The mice also develop dysfunctions in synaptic plasticity
[130] in conjunction with the early intraneuronal accumulation
of Aβ. More recently, this group has demonstrated that these
mice present with an impairment of long-term memory retention
at 4 months of age, indicating that intraneuronal Aβ may be
involved in the onset of cognitive deterioration. Feng et al. [63]
in reported studies on conditional deletion of PS1 and PS2 in the
adult mouse. The loss of presenilin activity in adult mice
resulted in forebrain degeneration, evident through cortical
shrinkage, together with enlargement of the lateral and third
ventricles. These are hallmark features in the brains of AD
patients with advanced disease [63]. They also uncovered a
series of cellular aberrations in these mice such as neuronal
atrophy, astrogliosis, apoptosis and tau hyperphosphorylation.
These results implicate the presenilins in the maintenance of
cortical structures and functions [63].
In addition to these recent mouse models there are
approximately 20 other strains of transgenic mice based on
mutations in APP. However, the majority of these, particularly
the Tg2576 mouse model (harbours the Swedish APP
mutation), are missing important aspects of AD pathology,
namely the neurofibrillary tangles [131]. Furthermore these
transgenic mice present with memory loss but are lacking the
evident neurodegenerative features of AD, thus, they resemble
the latent phase of AD [131]. In comparison tau expressing
transgenic mice develop neurofibrillary tangles, have evident
neuronal loss and also present with other aspects of AD
associated neurodegeneration [131]. In one particular line of tau
transgenic mice containing the R406W tau mutation, aged
transgenic mice present with memory impairment, without any
obvious sensorimotor deficits [132]. Evidently there is a need to
develop a model that mimics all aspects of the pathogenic
cascade, from the triggering mechanisms of AD, to the latent
phase of the disease.
4.2. The use of zebrafish to model Alzheimer’s disease
pathology
The zebrafish is an effective and simple model organism for
studies of development and disease processes in the nervous
system [133]. Developmental features of early embryonic
patterning, early development of the nervous system and
particular cell fates have been characterised in the zebrafish.
The zebrafish as a vertebrate is more closely related to humans
than invertebrate models such as yeast, worms or flies. The
zebrafish is an advantageous model for genetic studies as it is
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oligonucleotides (MO), mRNA or transgenes. With these
technologies it is possible to make both subtle and drastic
changes in gene expression and observe the affects in the
developing transparent embryo. MOs can be designed to block
translation of a particular gene or to block the splicing of
particular exons into transcripts. Overexpression studies can
also be performed by injecting sense mRNA of a gene. For both
MO and mRNA injection, the phenotypic affects on embryonic
development usually only persist during embryogenesis (i.e.
2 days). Transgenic zebrafish can also be developed by using
efficient vectors such as the sleeping beauty transposase system
to insert genes under the control of tissue specific promoters.
Furthermore, conditionally expressed transgenics can be
generated using heatshock promoters and the Cre/loxP and
GAL4-UAS systems for the analysis of gene function in
specific tissues at specific times [134].
Zebrafish embryos are a valuable system in which to study
presenilin function. Orthologues of PS1 and PS2 have been
identified in zebrafish (psen1 and psen2). Sequence alignment
of zebrafish and human presenilin protein sequences displays
these primary structures as being highly conserved, though
there are highly variable regions at the N-terminus and the C-
terminal half of the cytoplasmic loop domains. Transcripts from
zebrafish psen1 are ubiquitously expressed from fertilisation in
the zebrafish. This implies that zebrafish psen1 has an essential
function throughout embryonic development [120]. Similar to
full-length human PSEN1, zebrafish psen1 cDNA stably
transfected in HEK 293 cells, is rapidly turned over with very
little being turned into stable CTFs [120]. However, in vivo the
CTF concentration of zebrafish psen1 steadily increases during
embryogenesis to 24 h post fertilisation (hpf), suggesting
developmental regulation [122]. Zebrafish psen2 mRNA is
present from fertilisation but protein expression has only been
detected from the onset of gastrulation (6 hpf).
Pen-2 is a critical member of the γ-secretase complex. It is
thought to facilitate the endoproteolysis of PS1 [135], thus
conferring γ-secretase activity. Both zebrafish Pen-2 and
zebrafish Aph-1 (another member of the γ-secretase complex)
are present from fertilisation similar to psen1. At 12 hpf both
genes are ubiquitously expressed in the embryo and by 24 hpf
they are expressed predominantly in the brain [136]. Injection of
MO blocking Pen-2 translation led to a reduction in islet-1
positive neurons along the spinal cord, a reduction in Notch
signalling, an impairment of somitogenesis and induced
apoptosis throughout the whole fish [136]. The loss of islet-1
positive neurons in the spinal cord and the increase in apoptosis
could be rescued by a concurrent knockdown of p53, implying
that loss of Pen-2 induces a p53-dependent apoptotic pathway
[136]. The p53-dependant apoptotic pathway contributes to
neuronal loss, therefore Pen-2 may have a protective function
against apoptosis and promote neuronal survival in vivo.
By modulating presenilin expression, it is possible to
elucidate its function and regulation in zebrafish. DAPT is a
known γ-secretase inhibitor that reduces Aβ peptide levels in
the brain [137]. DAPT treatment impairs Notch processing
through an interference of presenilin function [138] resulting insevere side affects of γ-secretase inhibitors on Notch dependent
cell fate decisions [138]. Treatment of embryos with DAPT
affects somitogenesis and neurogenesis by 24 hpf [138]. This
phenotype is indistinguishable from Notch signalling deficien-
cies and can be rescued by injection of mRNA encoding the
NICD fragment of zebrafish Notch1. Injection of MOs that
block psen1 transcript translation, leads to disruption of somite
formation consistent with partial loss of Notch signalling in the
presomitic mesoderm [122]. There is a disruption of myoD
expression, a phenotype that is similar in mice lacking PS1
activity. Such mice have a milder phenotype than Notch1 null
mutant mice and this has been attributed to the redundant
activity of mouse PS2 [139]. However, PS2 knockout alone
does not produce a notch phenotype [139]. The possible
redundancy between mouse PS1 and PS2 in notch signalling is
not reflected in the activity of zebrafish psen1 and psen2.
Overexpression of zebrafish psen2 by microinjection of psen2
mRNA does not appear to regulate transcription of psen1 in
early zebrafish embryos (12 hpf) [122]. In contrast to
observations in mouse cell culture [140], overexpression of
PS2 also does not alter the level of endogenous PS1 holoprotein
[122]. Indeed, similar for psen1, repression of psen2 function in
zebrafish embryos provides notch loss of function phenotypes
[141]. These studies indicate that zebrafish embryos are a valid
and valuable system for the study of presenilin function and
regulation.
Two homologues of APP, appa and appb have been
identified in zebrafish. Both genes have approximately 70%
amino acid identity to human APP-695, with 80% identity in the
Aβ-42 region and 95% identity within the transmembrane
domain [142]. Widespread expression of both genes is first
detected at 8 hpf but at 10 hpf the distribution of expression of
two genes diverges. By 24 hpf both genes have overlapping but
distinct patterns of expression. Overall the expression pattern of
these two genes is similar to that observed for the mouse APP-
695 isoform [143]. This indicates that APP gene function is
conserved during vertebrate evolution.
Zebrafish are useful for studies of the effects of environ-
mental hazards on vertebrate cells. Similar to mammals, the
zebrafish have defence mechanisms against toxic chemicals
that includes the generation of oxidative stress [144]. Carvan
et al. [144] treated zebrafish and human cell lines with a
variety of chemicals known to induce transcription of certain
protective genes in cultured mammalian cells. They observed
activation of transcription of these genes in a similar dose
dependent manner in the zebrafish and human cells, indicating
this process to be well conserved between mammals and
zebrafish [144].
Alzheimer’s disease is clearly a complex, heterogenous
disorder evident through extensive research spanning from
oxidative stress mechanisms to vascular dysfunction. Intense
research has identified genes and environmental factors that
heighten the risk of developing AD. The pathogenesis of AD
may occur through several pathways, with the common
characteristics of Aβ deposition and to a lesser extent aberrant
presenilins, which have also been demonstrated in other
neurodegenerative disorders. Easily manipulable vertebrate
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increasingly important in elucidating these pathways.
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